MCR Syndrome in Quebec : Results From NuAge Study

Aging Disorder Clinical Trial

Official title:

The "Motoric Cognitive Risk" Syndrome in the Quebec Population: Results From the NuAge Study - Sub-study: The Biological Underpinnings of Motoric Cognitive Risk Syndrome: a Multicenter Study

Clinical Trial Details — Status: Active, not recruiting

Administrative data

• NCT number: NCT05046275
• Other study ID #: 2021-245
• Status: Active, not recruiting
• Start date: November 3, 2020
• Est. completion date: December 1, 2025

Study information

• Verified date: February 2024
• Source: Centre integre universitaire de sante et de services sociaux du Centre-Sud-de-l'Île-de-Montréal
• Contact: n/a
• Is FDA regulated: No
• Study type: Observational

Clinical Trial Summary

The overall objective of the proposal is to examine the epidemiology of the newly reported "motoric cognitive risk" (MCR) syndrome, which is a pre-dementia syndrome combining subjective cognitive complaint (i.e.; memory complaint) with objective slow gait speed, in the Quebec elderly population. Cognition and locomotion are two human abilities controlled by the brain. Their decline is highly prevalent with physiological and pathological aging, and is greater than the simple sum of their respective prevalence, suggesting a complex age-related interplay between cognition and locomotion. Both declines in cognition and locomotion are associated, furthermore the temporal nature of their association has been unclear for a long time. Recently, a systematic review and meta-analysis has provided evidence that poor gait performance predicts dementia and, in particular, has demonstrated that MCR syndrome is a pre-dementia syndrome, suggesting that low gait performance is the first symptom of dementia. The uniqueness of MCR syndrome is that it does not rely on a complex evaluation or laboratory investigations. Indeed, this syndrome combined subjective cognitive complaint and objective slow gait speed, and is easy to apply in population-based settings. Prevalence and incidence of MCR syndrome, as well as its association with incidence of cognitive decline and impairment, have never been reported in Canada. Nutrition as a determinant of successful aging: The Quebec longitudinal Study (the NuAge study) is a Quebec population-based observational cohort study performed in healthy older community-dwellers adults which provides a unique opportunity to: 1) obtain reliable estimates of MCR syndrome prevalence and incidence, 2) determine the distribution of clinical and biological (blood biomarkers and genetic) characteristics associated with MCR syndrome, 3) examine the association of MCR syndrome and its biological characteristics with cognitive decline and incidence of cognitive impairment in the Quebec elderly population.

Recruitment information / eligibility

• Status: Active, not recruiting
• Enrollment: 1741
• Est. completion date: December 1, 2025
• Est. primary completion date: November 2, 2025
• Gender: All
• Age group: 65 Years and older

Eligibility

Inclusion Criteria:

• All included participants of NuAge Study

Exclusion Criteria:

• no information about cognitive complaint in NuAge database
• no measure of walking speed in NuAge database
• no follow-up completed in NuAge database

Related Conditions & MeSH terms

• Aging Disorder
• Motoric Cognitive Risk Syndrome
• Syndrome

Intervention

Other:
• Data analysis
No intervention, data analysis only

Locations

Country	Name	City	State
Canada	CRIUGM	Montréal	Quebec

Sponsors (1)

Lead Sponsor	Collaborator
Centre integre universitaire de sante et de services sociaux du Centre-Sud-de-l'Île-de-Montréal

Country where clinical trial is conducted

Canada, 

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	prevalence of MCR syndrome	Diagnosis of MCR syndrome following Verghese et al. criteria	3 years
Secondary	Cognitive decline and impairment	Modified Mini-Mental State (3MS) in the NuAge study.	3 years
Secondary	Covariates	Cardio-vascular risk factors and diseases assessed using reported health condition	3 years
Secondary	Covariates	Cardio-vascular risk factors and diseases assessed using physical examination: body mass index	3 years
Secondary	Covariates	Cardio-vascular risk factors and diseases assessed using physical examination: hip waist ratio from hip and waist circumference	3 years
Secondary	Covariates	Cardio-vascular risk factors and diseases assessed using physical examination: blood pressure (value of systolic, diastolic when participants are seated in an upright position in a chair)	3 years
Secondary	Biological characteristics	we selected biomarkers that consistently show associations with clinical risk factors for MCR : IL-6, high-sensitivity CRP and Malondialdehyde (MDA). These biomarkers are associated with individual MCR components. CRP was associated with plaques. Inflammation is hypothesized to be a precursor to neurofibrillary tangles and amyloid plaques; hallmarks of AD. Oxidative stress damage is elevated in vulnerable brain regions in early AD and MCI.; We propose a multi-level examination of vascular pathways in MCR including biomarkers (CRP and homocysteine).; We include homocysteine, a vascular biomarker, linked to gait and cognitive deficits in other studies.	3 years
Secondary	Genetic approach	we propose to derive polygenic risk scores for cognitive and obesity phenotypes in NuAge, and to examine its predictive validity for MCR syndrome and incident cognitive impairment	3 years